v3.25.1
Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
Schedule of Restrictions on Cash and Cash Equivalents The following table provides a reconciliation of the total cash, cash equivalents and restricted cash reported on the Condensed Consolidated Balance Sheets to the corresponding amounts reported on the Condensed Consolidated Statements of Cash Flows.
March 31,
2025		March 31,
2024
Cash and cash equivalents$426 $263 
Restricted cash12 45 
Cash, cash equivalents and restricted cash$438 $308 
Schedule of Cash and Cash Equivalents The following table provides a reconciliation of the total cash, cash equivalents and restricted cash reported on the Condensed Consolidated Balance Sheets to the corresponding amounts reported on the Condensed Consolidated Statements of Cash Flows.
March 31,
2025		March 31,
2024
Cash and cash equivalents$426 $263 
Restricted cash12 45 
Cash, cash equivalents and restricted cash$438 $308 
Schedule of Shares Used in Computing Basic and Diluted Earnings Per Share Shares used in computing basic and diluted earnings per share are as follows: 
Three Months Ended
March 31,		Six Months Ended
March 31,
 2025202420252024
Denominator (thousands of shares):
Weighted-average common shares outstanding — basic214,976 209,826 214,965 209,789 
Incremental shares issuable for stock options, common stock awards, and Equity Units (a)(b)757 5,419 684 5,604 
UGI Corporation Senior Notes (c)3,211 — 1,682 — 
Weighted-average common shares outstanding — diluted218,944 215,245 217,331 215,393 
(a)For the three months ended March 31, 2025 and 2024, there were 6,121 and 8,659 shares, respectively, associated with outstanding stock option awards that were not included in the computation of diluted earnings per share above because their effect was antidilutive. For the six months ended March 31, 2025 and 2024, there were 6,915 and 8,468 shares, respectively, associated with outstanding stock option awards that were not included in the computation of diluted earnings per share above because their effect was antidilutive.
(b)The Equity Units were settled in June 2024. See Note 13 in the Company’s 2024 Annual Report for additional information on the Equity Units.
(c)See Note 8 for additional information on the UGI Corporation Senior Notes.